Regeneron makes strides in global Eylea patent enforcement campaign: settles with Sandoz, files fresh UK suits

Counsel

In the U.S. case, Regeneron was represented by Williams & Connolly’s David I. Berl, Ellen E. Oberwetter, Thomas S. Fletcher, Andrew V. Trask, Teagan J. Gregory, Shaun P. Mahaffy, Kathryn S. Kayali, Arthur J. Argall, Adam Pan, Rhochelle Krawetz, and Jennalee Beazley, as well as Paul, Weiss, Rifkind, Wharton & Garrison’s Elizabeth Stotland Weiswasser, Christopher M. Pepe, and Priyata Y. Patel, and Kellogg, Hansen, Todd, Figel & Frederick’s Andrew E. Goldsmith, Evan T. Leo, Jacob E. Hartman, Mary Charlotte Y. Carroll, and Sven E. Henningson, and Carey Douglas Kessler & Ruby’s Steven R. Ruby, David R. Pogue, and Raymond S. Franks II.

Meanwhile, Sandoz was represented by Wilentz, Goldman & Spitzer’s Edward T. Kole, as well as a team at Goodwin Procter: Emily L. Rapalino, Grace Truong, Joshua Weinger, Louis L. Lobel, Molly R. Grammel, Timothy James Beavers, Christopher Cassella, and Elaine Herrmann Blais.

In the new UK suit, Regeneron is being represented by a team at A&O Shearman.

Regeneron’s wider patent enforcement campaign

Regeneron has sued several of its rivals in different district courts over its Eylea drug under the BPCIA – all of which have been moved to the Northern District of West Virginia. Below is a table breaking down those cases so far:

Defendant	Number of patents asserted	Drug name	Date filed	Current status
Amgen	32	Pavblu	January 2024	Regeneron filed for a preliminary injunction, but that was denied by the district court in October 2024 – a decision affirmed by the Federal Circuit in March.
Mylan/Biocon	32	Yesafili	August 2022	Settled in April 2025.
Celltrion	25 (initially 38 but narrowed in a new complaint in May 2024)	CT-P42	November 2023	Regeneron filed for a preliminary injunction, which was granted by the district court in June 2024, and affirmed by the Federal Circuit in March.
Formycon	39	Ahzantive	November 2023	Regeneron filed for a preliminary injunction, which was granted by the district court in June 2024, and affirmed by the Federal Circuit in January.
Samsung Bioepis	37	Opuviz	November 2023	Regeneron filed for a preliminary injunction, which was granted by the district court in June 2024, and affirmed by the Federal Circuit in January.